Nanotics LLC has established a research collaboration with Mass General Cancer Center (MGCC), a program of Massachusetts General Hospital (MGH), to develop Nanots that target the soluble forms of tumor necrosis factor (TNF) receptors (sTNF-Rs).
Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. has synthesized new antibody-drug conjugates (ADC) or antigen binding fragments targeting claudin 18 (CLDN18) and linked to cytotoxic drug reported to be useful for the treatment of cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has presented new Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Institute of Organic Chemistry and Zai Lab (US) LLC have described new receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis, psoriasis, inflammatory bowel disease, inflammation, macular degeneration, systemic lupus erythematosus and arthritis, among other disorders.
Molecure SA presented data on the discovery of the clinical candidate OATD-02, a first-in-class, highly potent dual arginase-1/2 (ARG1/2) inhibitor with excellent activity against intracellular ARG2, thereby holding promise as an immunotherapeutic for cancer.
Monte Rosa Therapeutics Inc. has received FDA clearance of its IND application for MRT-2359, a potent and selective GSPT1-directed molecular glue degrader (MGD).
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis type 1, Noonan syndrome and Legius syndrome (neurofibromatosis type 1-like syndrome).
Collagen is the most abundant protein in the human body, which would seem to make it an unlikely source for an immunotherapy target. But it is where researchers from Immatics Biotechnologies GmbH and the University of Pennsylvania have found a target that was expressed on stromal cells in a number of different solid tumors, but very rare in normal tissues.
Doxorubicin is widely used as an anticancer agent, but it is associated with cardiotoxicity. Follistatin like 3 (FSTL3) is known to be involved in the regulation of cardiac hypertrophy and heart failure.
RSS
